Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

bortezomib

  • You have access
    Impact of Concomitant Use of Azoles on Bortezomib-related Adverse Drug Reactions Using JADER
    TAKUYA IMATOH, TAICHI MATSUMOTO, YUTAKA HARAMAKI and KEISUKE MIGITA
    Anticancer Research March 2023, 43 (3) 1341-1349; DOI: https://doi.org/10.21873/anticanres.16282
  • You have access
    Study of the Acquisition of Sensitivity to Paclitaxel Plus Cetuximab by the Addition of Low-dose Proteasome Inhibitor
    MASAKI YODA, KANAME SAKUMA, TOMOYUKI KII and AKIRA TANAKA
    Anticancer Research September 2022, 42 (9) 4273-4283; DOI: https://doi.org/10.21873/anticanres.15927
  • You have access
    Compound Library Screening for Synergistic Drug Combinations: mTOR Inhibitor and Proteasome Inhibitor Effective Against Osteosarcoma Cells
    KUNIHIRO ASANUMA, TOMOKI NAKAMURA, KOICHI NAKAMURA, TOMOHITO HAGI, TAKAYUKI OKAMOTO, KOUJI KITA, YUMI MATSUYAMA, KEISUKE YOSHIDA, YUMIKO ASANUMA and AKIHIRO SUDO
    Anticancer Research September 2022, 42 (9) 4319-4328; DOI: https://doi.org/10.21873/anticanres.15932
  • You have access
    Inhibition of Neurotoxicity/Anticancer Activity of Bortezomib by Caffeic Acid and Chlorogenic Acid
    REONA MATSUDA, HIROSHI SAKAGAMI, SHIGERU AMANO, YOSUKE IIJIMA, MOTOHIKO SANO, YOSHIHIRO UESAWA, NOBUAKI TAMURA, YOHEI OISHI and HIROSHI TAKESHIMA
    Anticancer Research February 2022, 42 (2) 781-790; DOI: https://doi.org/10.21873/anticanres.15536
  • You have access
    Protection of Bortezomib-induced Neurotoxicity by Antioxidants
    YOSUKE IIJIMA, KENJIRO BANDOW, SHIGERU AMANO, MOTOHIKO SANO, SHUNSUKE HINO, TAKAHIRO KANEKO, NORIO HORIE and HIROSHI SAKAGAMI
    Anticancer Research July 2020, 40 (7) 3685-3696; DOI: https://doi.org/10.21873/anticanres.14357
  • You have access
    Incorporating Bortezomib in the Management of Plasmablastic Lymphoma
    ONYEDIKA UMEANAETO, JOSEPH GAMBOA, JESUS DIAZ, M. NAWAR HAKIM, JAVIER CORRAL, ALEXANDER PHILIPOVSKIY and SUMIT GAUR
    Anticancer Research September 2019, 39 (9) 5003-5007; DOI: https://doi.org/10.21873/anticanres.13690
  • You have access
    Bortezomib Is More Effective to Side Population of RPMI8226 Myeloma Cells than Classical Anti-myeloma Agents
    KYOUNG HA KIM, HEE-JEONG CHEONG, MIN YOUNG LEE, NAMSU LEE, KYU-TAEK LEE, SEONG KYU PARK and JONG-HO WON
    Anticancer Research January 2019, 39 (1) 127-133; DOI: https://doi.org/10.21873/anticanres.13088
  • You have access
    High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib
    KANA OIWA, MIHOKO MORITA, SHINJI KISHI, MIYUKI OKURA, TOSHIKI TASAKI, YASUFUMI MATSUDA, KATSUNORI TAI, NAOKO HOSONO, TAKANORI UEDA and TAKAHIRO YAMAUCHI
    Anticancer Research December 2016, 36 (12) 6655-6662;
  • You have access
    Preclinical Evaluation of Combined Targeted Approaches in Malignant Rhabdoid Tumors
    NATALIA MORENO and KORNELIUS KERL
    Anticancer Research August 2016, 36 (8) 3883-3887;
  • You have access
    Bortezomib, Thalidomide and Lenalidomide: Have They Really Changed the Outcome of Multiple Myeloma?
    MICHAEL MIAN, MARTINA TINELLI, ELENA DE MARCH, GLORIA TURRI, VITTORIO MENEGHINI, NORBERT PESCOSTA, TAMARA BERNO, ALESSANDRA MARABESE, PATRIZIA MONDELLO, FRANCESCA PATRIARCA, GIOVANNI PIZZOLO, GIANPIETRO SEMENZATO, SERGIO CORTELAZZO and RENATO ZAMBELLO
    Anticancer Research March 2016, 36 (3) 1059-1065;

Pages

  • Next
  • 1
  • 2
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire